Abstract
Objective The purpose of the current study was to compare the diagnostic accuracies of F-18 FDG PET/CT and MRI for prediction of pathologic responses to neoadjuvant treatment (NAT) in locally advanced rectal cancer (LARC) patients based on a systematic review and meta-analyses. Methods The PubMed, Cochrane, and Embase databases were searched to identify studies that conducted direct comparisons of the diagnostic performance of F-18 FDG PET/CT and MRI for the prediction of pathologic response to NAT in patients with LARC from the earliest available date of indexing up to July 31, 2020. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR + and LR −), and we constructed summary receiver operating characteristic curves. Results In nine studies (427 patients), the pooled sensitivity of F-18 FDG PET/CT was 0.79 (95% CI 0.71–0.86) and the pooled specificity was 0.74 (95% CI 0.60–0.84). LR syntheses yielded an overall LR + of 3.1 (95% CI 1.9–5.0) and an LR − of 0.28 (95% CI 0.18–0.43). The pooled diagnostic odds ratio (DOR) was 11 (95% CI 5–26). The pooled sensitivity of MRI was 0.89 (95% CI 0.77–0.95) and the pooled specificity was 0.66 (95% CI 0.55–0.76). LR syntheses yielded an overall LR + of 2.6 (95% CI 1.9–3.6) and an LR − of 0.17 (95% CI 0.08–0.37). The pooled DOR was 15 (95% CI 6–42). In meta-regression analysis, no variable was identified as the source of the study heterogeneity. Conclusion F-18 FDG PET/CT and MRI showed similar diagnostic performances for the prediction of pathologic responses to NAT in patients with LARC. However, each modality can be a complement to other rather than being used singly.

This publication has 40 references indexed in Scilit: